Literature DB >> 25070493

New options of antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa.

I Nakamura1, T Yamaguchi2,3, A Tsukimori1,4, A Sato1,4, S Fukushima1, T Matsumoto4.   

Abstract

Several antibiotic combinations have demonstrated increased activity against multidrug-resistant Pseudomonas aeruginosa (MDRP) in vitro compared with a single antibiotic. The aim of this study was to investigate the activity against MDRP of some aminoglycosides in combination with monobactam, piperacillin (PIPC), and carbapenem. Clinical isolates of MDRP were collected between November 2010 and October 2012 from patients in Tokyo Medical University Hospital, Tokyo (1,015 beds). Our new method was designed to evaluate three concentrations around the breakpoint of each drug using the Checkerboard method. The aminoglycosides tested were amikacin (AMK), tobramycin (TOB), and arbekacin (ABK). Ciprofloxacin, PIPC, and biapenem (BIPM), which have been reported to demonstrate combination effects, were also tested. Sixty-six MDRP strains were identified from the 2,417 P. aeruginosa strains. Of the 66, 27 tested positive for metallo-β-lactamase (MBL). Aztreonam (AZT) with AMK or ABK was the most effective against MDRP. PIPC with AMK or ABK were somewhat effective. AZT with AMK or ABK were more effective against MBL-positive strains than MBL-negative strains. However, PIPC with AMK or ABK were more effective against MBL-negative strains than MBL-positive strains. Combination activities showed differences between MBL-positive and MBL-negative strains.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25070493     DOI: 10.1007/s10096-014-2192-x

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  12 in total

1.  In vitro combination effects of aztreonam and aminoglycoside against multidrug-resistant Pseudomonas aeruginosa in Japan.

Authors:  Hideki Araoka; Masaru Baba; Kazuhiro Tateda; Yoshikazu Ishii; Toyoko Oguri; Katsuko Okuzumi; Tsuyoshi Oishi; Shinichiro Mori; Toshihiro Mitsuda; Kyoji Moriya; Yoshitaka Nakamori; Norio Ohmagari; Keizo Yamaguchi; Akiko Yoneyama
Journal:  Jpn J Infect Dis       Date:  2012       Impact factor: 1.362

Review 2.  Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.

Authors:  Matthew E Falagas; Sofia K Kasiakou
Journal:  Clin Infect Dis       Date:  2005-03-22       Impact factor: 9.079

3.  Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus.

Authors:  T Watanabe; K Ohashi; K Matsui; T Kubota
Journal:  J Antimicrob Chemother       Date:  1997-04       Impact factor: 5.790

4.  The fractional inhibitory concentration (FIC) index as a measure of synergy.

Authors:  M J Hall; R F Middleton; D Westmacott
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

5.  IMP-12, a new plasmid-encoded metallo-beta-lactamase from a Pseudomonas putida clinical isolate.

Authors:  Jean-Denis Docquier; Maria Letizia Riccio; Claudia Mugnaioli; Francesco Luzzaro; Andrea Endimiani; Antonio Toniolo; Gianfranco Amicosante; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

6.  Effectiveness of antibiotic combination therapy as evaluated by the Break-point Checkerboard Plate method for multidrug-resistant Pseudomonas aeruginosa in clinical use.

Authors:  Itaru Nakamura; Tetsuo Yamaguchi; Ayaka Tsukimori; Akihiro Sato; Shinji Fukushima; Yasutaka Mizuno; Tetsuya Matsumoto
Journal:  J Infect Chemother       Date:  2014-01-31       Impact factor: 2.211

7.  Biochemical characterization of the Pseudomonas aeruginosa 101/1477 metallo-beta-lactamase IMP-1 produced by Escherichia coli.

Authors:  N Laraki; N Franceschini; G M Rossolini; P Santucci; C Meunier; E de Pauw; G Amicosante; J M Frère; M Galleni
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

8.  Monobactam and aminoglycoside combination therapy against metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa screened using a 'break-point checkerboard plate'.

Authors:  Hideki Araoka; Masaru Baba; Shinsuke Takagi; Naofumi Matsuno; Kazuya Ishiwata; Nobuaki Nakano; Masanori Tsuji; Hisashi Yamamoto; Sachiko Seo; Yuki Asano-Mori; Naoyuki Uchida; Kazuhiro Masuoka; Atsushi Wake; Shuichi Taniguchi; Akiko Yoneyama
Journal:  Scand J Infect Dis       Date:  2010-03

9.  Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa.

Authors:  Peter K Linden; Shimon Kusne; Kim Coley; Paulo Fontes; David J Kramer; David Paterson
Journal:  Clin Infect Dis       Date:  2003-10-29       Impact factor: 9.079

10.  In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa.

Authors:  Shigeharu Oie; Toshinari Uematsu; Akihiro Sawa; Hidekazu Mizuno; Masaaki Tomita; Shiro Ishida; Yoshiro Okano; Akira Kamiya
Journal:  J Antimicrob Chemother       Date:  2003-10-29       Impact factor: 5.790

View more
  8 in total

1.  Identification of 1-((2,4-Dichlorophenethyl)Amino)-3-Phenoxypropan-2-ol, a Novel Antibacterial Compound Active against Persisters of Pseudomonas aeruginosa.

Authors:  Veerle Liebens; Valerie Defraine; Wouter Knapen; Toon Swings; Serge Beullens; Romu Corbau; Arnaud Marchand; Patrick Chaltin; Maarten Fauvart; Jan Michiels
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.

Authors:  Douglas J Biedenbach; Krystyna Kazmierczak; Samuel K Bouchillon; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

3.  Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia.

Authors:  Helio S Sader; Paul R Rhomberg; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

4.  Synergistic action of substituted indole derivatives and clinically used antibiotics against drug-resistant bacteria.

Authors:  Danielle N Turner; Leslie Edwards; Alexander Kornienko; Liliya V Frolova; Snezna Rogelj
Journal:  Future Microbiol       Date:  2020-06-02       Impact factor: 3.165

5.  Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections.

Authors:  Juan José Castón; Álvaro De la Torre; Isabel Ruiz-Camps; María Luisa Sorlí; Vicente Torres; Julián Torre-Cisneros
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

Review 6.  Clinical Usefulness of Arbekacin.

Authors:  Jae Hoon Lee; Chang-Seop Lee
Journal:  Infect Chemother       Date:  2016-03-31

7.  Clinical Efficacy and Safety of Arbekacin against Pneumonia in Febrile Neutropenia: A Retrospective Study in Patients with Hematologic Malignancies.

Authors:  Takashi Ohashi; Yukiyoshi Fujita; Hiroyuki Irisawa; Hidemasa Nakaminami; Takahiro Arai; Masumi Takahashi; Emi Momiyama; Naoya Murata; Kayoko Murayama; Taeko Saito
Journal:  Infect Chemother       Date:  2022-03

8.  Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.

Authors:  Nicholas Rebold; Taylor Morrisette; Abdalhamid M Lagnf; Sara Alosaimy; Dana Holger; Katie Barber; Julie Ann Justo; Kayla Antosz; Travis J Carlson; Jeremy J Frens; Mark Biagi; Wesley D Kufel; William J Moore; Nicholas Mercuro; Brian R Raux; Michael J Rybak
Journal:  Open Forum Infect Dis       Date:  2021-12-09       Impact factor: 3.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.